Skip to main content

Drug Interactions between cipaglucosidase alfa and Lumizyme

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

alglucosidase alfa cipaglucosidase alfa

Applies to: Lumizyme (alglucosidase alfa) and cipaglucosidase alfa

ADJUST DOSING INTERVAL: Enzyme replacement therapies used for the treatment of Pompe disease have not been evaluated in combination. Clinical data are not available.

MANAGEMENT: The manufacturer of cipaglucosidase alfa recommends that patients transitioning from another enzyme replacement therapy (ERT) to cipaglucosidase alfa combined with miglustat therapy start cipaglucosidase alfa-miglustat at the next scheduled dosing time (i.e., approximately 2 weeks after the last ERT administration). Additionally, if the patient required pretreatment with antihistamines, antipyretics, and/or corticosteroids before the previous ERT therapy, they recommend continuing to receive those medications prior to their cipaglucosidase alfa infusion.

References

  1. (2023) "Product Information. Pombiliti (cipaglucosidase alfa)." Amicus Therapeutics U.S., Inc.
  2. (2023) "Product Information. Pombiliti (cipaglucosidase alfa)." Amicus Therapeutics UK Operations Ltd

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Agents for pompe disease

Therapeutic duplication

The recommended maximum number of medicines in the 'agents for Pompe disease' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'agents for Pompe disease' category:

  • cipaglucosidase alfa
  • Lumizyme (alglucosidase alfa)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer